Debbie Urioste
Family Medicine · Colorado Springs, CONPI 1326071051
Payments from drug & device makers
Across 81 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$181
- Neurocrine Biosciences, Inc.$134
- Lilly USA, LLC$131
- Novo Nordisk$116
- AbbVie$112
- Johnson & Johnson$110
- plus $591 from 18 others
What the payments were for
- Food & beverage$1,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $181 |
| Neurocrine Biosciences, Inc. | 1 | $134 |
| Lilly USA, LLC | 12 | $131 |
| Novo Nordisk | 7 | $116 |
| AbbVie | 6 | $112 |
| Johnson & Johnson(2 entities) | 7 | $110 |
| AstraZeneca | 7 | $106 |
| Upsher-smith Laboratories LLC | 3 | $59 |
| Astellas Pharma US Inc | 3 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $51 |
| Boehringer Ingelheim | 3 | $40 |
| Pfizer | 2 | $25 |
| Merck | 2 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Gilead | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| IBSA Pharma Inc. | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$134
How this compares
$1,375 in reported general payments places this provider in the 80th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $28,271 |
| OzempicSemaglutide | 16 | $15,824 |
| XareltoRivaroxaban | 25 | $12,423 |
| Pantoprazole Sodium | 70 | $4,716 |
| Sucralfate | 15 | $4,045 |
| Esomeprazole Magnesium | 21 | $3,239 |
| Buprenorphine | 12 | $2,531 |
| Midodrine Hcl | 12 | $2,471 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,081 |
| Duloxetine Hcl | 37 | $1,585 |
| Quetiapine Fumarate | 31 | $1,175 |
| Rosuvastatin Calcium | 28 | $1,154 |
| Bupropion XlBupropion Hcl | 26 | $1,141 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $1,073 |
| ClopidogrelClopidogrel Bisulfate | 33 | $850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $28,27157 claims |
| Novo NordiskOzempic | $116 | $15,82416 claims |
| Johnson & JohnsonXarelto | $110 | $12,42325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Colorado Springs
- Ripley HollisterColorado Springs$5.5M
- Matthew YoungColorado Springs$270K
- Lawrence AndrewsColorado Springs$102K
- Jeffrey SnyderColorado Springs$31K
- Elizabeth EricksonColorado Springs$31K
- Daniel RohwederColorado Springs$21K
- Stephen FarkasColorado Springs$20K
- Max NevarezColorado Springs$15K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.